AstraZeneca's profit and sales grew last quarter, and it plans to save $1.5 billion to boost its drug lineup.

Oct 30, 2026, 3:39 AM ETResultsRead the original at marketscreener.com

Good for AZN

AstraZeneca reported third-quarter sales and profit growth, and Imfinzi sales rose 26% at constant currency. It repeated its full-year forecast rather than raising it, but positive Phase III trial results and planned research savings make the report favorable.

AZN · AstraZeneca

AI read · Good for AZN

The AI's read

The report adds support for AstraZeneca's business outlook. Growing sales and profit show the business expanded, and Imfinzi's rise points to strength in cancer medicines. Positive Phase III trial results add support for its drug pipeline. The $1.5 billion savings plan is meant to fund more research. AstraZeneca repeated its full-year forecast rather than raising it, but the growth and trial news carry more weight.

Get alerts for AZN

Follow AstraZeneca (AZN) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for AZN

Free on the App Store and Google Play, or on the web.